NO180448C - Heksacyklisk forbindelse - Google Patents

Heksacyklisk forbindelse

Info

Publication number
NO180448C
NO180448C NO920201A NO920201A NO180448C NO 180448 C NO180448 C NO 180448C NO 920201 A NO920201 A NO 920201A NO 920201 A NO920201 A NO 920201A NO 180448 C NO180448 C NO 180448C
Authority
NO
Norway
Prior art keywords
compound
antitumour
hexacyclic compound
abundantly
camptothecin
Prior art date
Application number
NO920201A
Other languages
English (en)
Norwegian (no)
Other versions
NO920201L (no
NO180448B (no
NO920201D0 (no
Inventor
Hirofumi Terasawa
Akio Ejima
Satoru Ohsuki
Kouichi Uoto
Original Assignee
Daiichi Seiyaku Co
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co, Yakult Honsha Kk filed Critical Daiichi Seiyaku Co
Publication of NO920201D0 publication Critical patent/NO920201D0/no
Publication of NO920201L publication Critical patent/NO920201L/no
Publication of NO180448B publication Critical patent/NO180448B/no
Publication of NO180448C publication Critical patent/NO180448C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Lubricants (AREA)
  • Fats And Perfumes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NO920201A 1991-01-16 1992-01-15 Heksacyklisk forbindelse NO180448C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1581291 1991-01-16

Publications (4)

Publication Number Publication Date
NO920201D0 NO920201D0 (no) 1992-01-15
NO920201L NO920201L (no) 1992-07-17
NO180448B NO180448B (no) 1997-01-13
NO180448C true NO180448C (no) 1997-04-23

Family

ID=11899258

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920201A NO180448C (no) 1991-01-16 1992-01-15 Heksacyklisk forbindelse

Country Status (15)

Country Link
EP (1) EP0495432B1 (fr)
JP (1) JP3008226B2 (fr)
KR (1) KR100191193B1 (fr)
AT (1) ATE138661T1 (fr)
AU (1) AU640549B2 (fr)
CA (1) CA2059305C (fr)
DE (1) DE69211023T2 (fr)
DK (1) DK0495432T3 (fr)
ES (1) ES2090366T3 (fr)
FI (1) FI103047B (fr)
GR (1) GR3020395T3 (fr)
HK (1) HK1001561A1 (fr)
IE (1) IE920079A1 (fr)
NO (1) NO180448C (fr)
RU (1) RU2071476C1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407115B1 (en) * 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5637770A (en) * 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
WO1996026181A1 (fr) * 1995-02-22 1996-08-29 Daiichi Pharmaceutical Co., Ltd. Derives d'aminotetralone et leurs procede de production
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
IN189180B (fr) * 1997-07-09 2003-01-04 Chong Kun Dang Corp
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
WO2002090315A1 (fr) * 2001-05-08 2002-11-14 Mitsui Chemicals, Inc. Procede de preparation de 1,5-diaminonaphtalenes
JP4305909B2 (ja) 2001-11-30 2009-07-29 中外製薬株式会社 六環式化合物
KR100501439B1 (ko) * 2002-09-27 2005-07-18 현대자동차주식회사 차량 충돌시 연료 누출 방지장치
CN1777611A (zh) * 2003-02-21 2006-05-24 中外制药株式会社 制备六环喜树碱衍生物的方法
CA2563502A1 (fr) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Nouveau promedicament soluble dans l'eau
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
ITMI20061475A1 (it) * 2006-07-26 2008-01-27 Indena Spa Derivati della camptotecina ad attivita antitumorale
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
EP2376088B1 (fr) 2008-12-23 2017-02-22 Gilead Pharmasset LLC Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
UY33311A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidatos de nucleosidos
SI3342785T1 (sl) 2012-10-11 2020-02-28 Daiichi Sankyo Company, Limited Povezovalci za konjugate protitelesa in zdravila
WO2014061277A1 (fr) 2012-10-19 2014-04-24 第一三共株式会社 Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
WO2015098099A1 (fr) 2013-12-25 2015-07-02 第一三共株式会社 Conjugué anticorps anti-trop2-médicament
RS62618B1 (sr) 2014-01-31 2021-12-31 Daiichi Sankyo Co Ltd Anti-her2 antitelo-lek konjugat
WO2015155976A1 (fr) 2014-04-10 2015-10-15 第一三共株式会社 Conjugué (anticorps anti-her2)-médicament
EP3129063B1 (fr) 2014-04-10 2021-01-27 Daiichi Sankyo Company, Limited Conjugué médicament-anticorps anti-her3
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
CN109789211A (zh) 2016-10-07 2019-05-21 第一三共株式会社 基于抗her2抗体-药物偶联物施予的耐性癌的治疗
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
IL268102B1 (en) 2017-01-17 2024-08-01 Daiichi Sankyo Co Ltd Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
BR112020003646A2 (pt) 2017-08-31 2020-09-01 Daiichi Sankyo Company, Limited cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
SG11202001514XA (en) * 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
SI3794042T1 (sl) 2018-05-18 2024-07-31 Daiichi Sankyo Co., Ltd. Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo
US20200306243A1 (en) * 2019-03-29 2020-10-01 Medimmune Limited Compounds and conjugates thereof
EP4093439A1 (fr) * 2020-01-22 2022-11-30 MedImmune Limited Composés et conjugués correspondants
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
CN111470998B (zh) * 2020-06-28 2020-09-25 上海皓元生物医药科技有限公司 用于合成喜树碱衍生物的中间体及其制备方法和用途
CA3200649A1 (fr) * 2020-12-11 2022-06-16 Yuli Xie Nouveau derive de camptothecine, composition le contenant et son utilisation
WO2022166762A1 (fr) * 2021-02-05 2022-08-11 四川科伦博泰生物医药股份有限公司 Composé camptothécine, son procédé de préparation et son application
WO2022171115A1 (fr) * 2021-02-09 2022-08-18 微境生物医药科技(上海)有限公司 Dérivé de camptothécine pour préparation d'adc
CN115703712A (zh) * 2021-08-17 2023-02-17 江苏迈威康新药研发有限公司 5,8-二氨基-3,4-二氢-2h-1-萘酮的合成方法以及其中采用的中间体化合物
CN115724758A (zh) * 2021-08-24 2023-03-03 杭州中美华东制药有限公司 喜树碱衍生物中间体及其合成方法和利用中间体合成喜树碱衍生物的方法
CN118119594A (zh) * 2021-10-26 2024-05-31 上海弼领生物技术有限公司 一种喜树碱类衍生物中间体、其制备方法和用途
EP4429709A1 (fr) 2021-11-09 2024-09-18 Tubulis GmbH Conjugués comprenant un phosphore (v) et un fragment de camptothécine
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Antibodies masked in protease-wells
AU2022408887A1 (en) * 2021-12-16 2024-07-18 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Camptothecin compound and conjugate thereof
WO2024020536A1 (fr) * 2022-07-22 2024-01-25 Nj Bio, Inc. Inhibiteurs de topoisomérase hexacyclique ayant une activité cytotoxique sur des cellules cancéreuses
TW202423928A (zh) * 2022-09-02 2024-06-16 美商默沙東有限責任公司 源自依克沙替康(exatecan)之拓樸異構酶-1抑制劑醫藥組合物及其用途
WO2024083926A1 (fr) 2022-10-18 2024-04-25 Tubulis Gmbh Nouveaux conjugués anticorps-médicament avec de nouveaux anticorps napi2b, procédés thérapeutiques et utilisations de ceux-ci
WO2024083953A1 (fr) 2022-10-18 2024-04-25 Tubulis Gmbh Nouvel anticorps anti-tpbg et conjugués anticorps-médicament basés sur celui-ci, procédés thérapeutiques et utilisations dudit anticorps
WO2024133845A1 (fr) 2022-12-22 2024-06-27 Tubulis Gmbh Conjugués comprenant une fraction phosphore (v) et un médicament
WO2024153159A1 (fr) * 2023-01-18 2024-07-25 上海森辉医药有限公司 Procédé de préparation de tétrahydro-1-naphtylamine et de ses dérivés

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives

Also Published As

Publication number Publication date
NO920201L (no) 1992-07-17
FI103047B1 (fi) 1999-04-15
AU1018592A (en) 1992-07-23
ATE138661T1 (de) 1996-06-15
FI920194A (fi) 1992-07-17
EP0495432A1 (fr) 1992-07-22
FI103047B (fi) 1999-04-15
DE69211023D1 (de) 1996-07-04
EP0495432B1 (fr) 1996-05-29
KR100191193B1 (ko) 1999-06-15
ES2090366T3 (es) 1996-10-16
NO180448B (no) 1997-01-13
JPH0559061A (ja) 1993-03-09
DE69211023T2 (de) 1997-01-09
HK1001561A1 (en) 1998-06-26
CA2059305C (fr) 2001-07-31
IE920079A1 (en) 1992-07-29
KR920014816A (ko) 1992-08-25
DK0495432T3 (da) 1996-10-21
GR3020395T3 (en) 1996-09-30
FI920194A0 (fi) 1992-01-16
RU2071476C1 (ru) 1997-01-10
NO920201D0 (no) 1992-01-15
JP3008226B2 (ja) 2000-02-14
CA2059305A1 (fr) 1992-07-17
AU640549B2 (en) 1993-08-26

Similar Documents

Publication Publication Date Title
DK0495432T3 (da) Hexacyclisk forbindelse
DK344488A (da) Hexacycliske forbindelser
CA2100258A1 (fr) Derives de l'acridine
GR3007919T3 (fr)
ATE21105T1 (de) 7-oxo-4-thia-1-aza(3.2.0)heptan- und 7-oxo-4-thia-1-aza-(3.2.0)hept-2-en-derivate.
YU69289A (en) Substituted flavonoidic compounds, their salts and process for producing thereof
ES2063186T3 (es) Derivados ftalinida, composicion farmaceutica y uso.
FI884077A (fi) Amidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande kompositioner foer aktivering av gastrisk motorfunktion.
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
DE69810373D1 (de) Pyrrolidin Derivate, Anti-ulcus und Antibakterielle Arzneimittel
IL97040A0 (en) Novel antibiotic,deoxymulundocandin,a process for its production and its use as medicament
ATE58129T1 (de) Dem antibiotikum tan-749 aehnliche verbindungen und ihre herstellung.
EP0357109A3 (en) Platinum-(ii)-diamine complex, method for the preparation of this compound, preparation with an anti-tumour action which contains this compound and also shaped preparations with an anti-tumour action
DK0412464T3 (da) Butalactin, en fremgangsmåde til dets fremstilling og dets anvendelse som lægemiddel